Korsana Biosciences, Inc. Common Stock (CYCN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
CYCN Chart
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Korsana Biosciences, Inc. Common Stock Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Sima Elimelech Activest Wealth Management | 14.3 | $230 | $48.05 | -$181.95 | -79.11% |
| KJ Ken Joseph Braidwel LLP | 22,435.27 | $531,850.51 | $76,055.55 | -$455,794.96 | -85.7% |
Korsana Biosciences, Inc. Common Stock (CYCN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Korsana Biosciences, Inc. Common Stock Profile
| Biotechnology Industry | Healthcare Sector | Regina Graul CEO | NASDAQ (CM) Exchange | 23255M204 CUSIP |
| US Country | 1 Employees | - Last Dividend | 9 Sep 2026 Last Split | 2 Apr 2019 IPO Date |
Overview
Cyclerion Therapeutics, Inc. is a pioneering biopharmaceutical company focused on the development of novel treatments for serious diseases. Incorporated in 2018 and based out of Cambridge, Massachusetts, Cyclerion is at the forefront of leveraging advanced science to target unmet medical needs. The company’s primary mission revolves around the innovation of therapeutic solutions that can substantially improve the lives of patients afflicted with serious diseases, particularly those related to cardiovascular and kidney conditions.
Products and Services
-
Olinciguat:
An orally administered vascular soluble guanylate cyclase (sGC) stimulator that is currently in Phase 2 clinical trials. Cyclerion is exploring the potential of Olinciguat to be out-licensed for the treatment of cardiovascular diseases. This innovative treatment option strives to offer a novel mechanism of action for addressing the underlying pathophysiology of a variety of cardiovascular conditions.
-
Praliciguat:
A systemic sGC stimulator that has been licensed to Akebia Therapeutics, Inc. Praliciguat is under development for the treatment of rare kidney diseases. The licensing agreement with Akebia Therapeutics represents a strategic move to maximize the therapeutic potential and reach of Praliciguat in addressing the needs of patients with challenging kidney conditions.
Contact Information
